Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

About this update from Bolt Biotherapeutics, Inc.

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif. , Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026 , and provided a business update. “In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer. We are currently treating patients in Cohort 4. To date, BDC-4182 has been well tolerated, and we are seeing activity consistent with our immune-stimulating mechanism,” said Willie Quinn , President and Chief Executive Officer. “We expect to report initial clinical data from BDC-4182 with our third quarter 2026 results.” Recent Highlights and Anticipated Milestones Initial clinical data from BDC-4182 Phase 1/2 study for patients with gastric and gastroesophageal cancer   expected with third quarter 2026 results. BDC-4182 is a next-generation Boltbody™ ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and other tumor types. In preclinical models, including cancer models with low claudin 18.2 expression, BDC-4182 demonstrated significant anti-tumor activity, induced immunological memory, and outperformed cytotoxic ADCs. Bolt has implemented step-up dosing, which has been successfully used commercially for T-cell engagers, as a strategy to get to higher doses safely. The clinical trial in gastric and gastroesophageal cancers is progressing well with ongoing treatment of patients in Cohort 4 at the 4.0 mg/kg dose level. Cash, cash equivalents, and marketable securities were $ 18.1 million as of June 30, 2026 . Cash on hand is expected to fund operations into the quarter 2027. Second Quarter 2026 Financial Results Collaboration Revenue – Total collaboration revenue was $5,000 for the quarter ended June 30, 2026 , compared to $1.8 million for the same quarter in 2025. Revenue in the comparative periods was generated from services performed under the R&D collaborations as we fulfill our performance obligations.  Research and Development (R&D) Expenses – R&D expenses were $5.1 million for the quarter ended June 30, 2026 , compared to $7.5 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a decrease in salary and related expenses primarily as a result of our restructuring and overall lower research and development activities.  General and Administrative (G&A) Expenses – G&A expenses were $2.4 million for the quarter ended June 30, 2026 , compared to $3.5 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a decrease in salary and related expenses primarily as a result of our restructuring as well as lower consulting expenses. Loss from Operations – Loss from operations was $8.4 million for the quarter ended June 30, 2026 , compared to $9.2 million for the same quarter in 2025. About the Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform Bolt Biotherapeutics’ Boltbody ISAC platform harnesses the precision of antibodies with the power of the innate and adaptive immune system to generate a productive anti-cancer response. Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant. The antibody is designed to target one or more markers on the surface of a tumor cell and the immune stimulant is designed to recruit and activate myeloid cells. Activated myeloid cells initiate a positive feedback loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This increases the population of activated immune system cells in the tumor microenvironment and promotes a robust immune response with the goal of generating durable therapeutic responses for patients with cancer. About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline reflects the Company’s expertise in myeloid biology and cancer drug development. The Company’s lead program is BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1/2 trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company’s Boltbody™ ISAC platform technology. The rest of the Company’s pipeline is currently on hold, including BDC-3042, a Dectin-2 agonist that completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1. For more information, please visit https://www.boltbio.com/ . Forward-Looking Statements This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our ability to partner our CEA ISAC and PD-L1 ISAC, the advancement and success of our BDC-4182 clinical trials, the timing of initial data from our Phase 1 dose-escalation study of BDC-4182, the timing of our ISAC programs, the anti-tumor potency, safety and tolerability, and characteristics of our product candidates, the initiation of future clinical trials, the potential value of collaborations, and the expected duration of our cash runway and ability to fund key milestones into first quarter 2027, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov. Investor Relations and Media Contact:     Matthew DeYoung Argot Partners (212) 600-1902 [email protected] BOLT BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited, in thousands, except share and per share amounts)       Three Months Ended June 30 ,     Six Months Ended June 30 ,       2026     2025     2026     2025   Collaboration revenue   $ 5     $ 1,804     $ 31     $ 3,026   Operating expenses:                         Research and development     5,149       7,498       9,978       17,010   General and administrative     2,422       3,516       5,220       7,341   Impairment charges     808       —       808       —   Total operating expense     8,379       11,014       16,006       24,351   Loss from operations     (8,374 )     (9,210 )     (15,975 )     (21,325 ) Other income (expense), net:                         Interest income, net     178       599       454       1,652   Other income, net     476       50       557       72   Total other income (expense), net     654       649       1,011       1,724   Net loss     (7,720 )     (8,561 )     (14,964 )     (19,601 ) Net unrealized loss on marketable securities     (33 )     (46 )     (23 )     (103 ) Comprehensive loss   $ (7,753 )   $ (8,607 )   $ (14,987 )   $ (19,704 ) Net loss per share, basic and diluted   $ (4.57 )   $ (4.46 )   $ (8.88 )   $ (10.22 ) Weighted-average shares outstanding, basic and diluted     1,690,529       1,917,629       1,685,514       1,917,288                                     BOLT BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands)       June 30 ,     December 31 ,       2026     2025   Assets             Current assets:             Cash and cash equivalents   $ 12,860     $ 11,703   Short-term investments     4,738       15,802   Restricted cash     200       200   Prepaid expenses and other current assets     2,766       2,555   Total current assets     20,564       30,260   Property and equipment, net     571       1,245   Operating lease right-of-use assets     17,075       19,230   Restricted cash, non-current     1,538       1,538   Long-term investments     509       4,337   Other assets     87       138   Total assets   $ 40,344     $ 56,748   Liabilities and stockholders' equity             Current liabilities:             Accounts payable   $ 868     $ 1,443   Accrued expenses and other current liabilities     3,089       3,717   Deferred revenue     819       449   Operating lease liabilities     3,091       2,826   Total current liabilities     7,867       8,435   Operating lease liabilities, net of current portion     18,533       20,132   Deferred revenue, non-current     1,172       1,544   Other long-term liabilities     132       132   Total liabilities     27,704       30,243   Commitments and contingencies             Stockholders' equity:             Common stock     —       —   Additional paid-in capital     488,427       487,305   Accumulated other comprehensive loss     (44 )     (21 ) Accumulated deficit     (475,743 )     (460,779 ) Total stockholders' equity     12,640       26,505   Total liabilities and stockholders' equity   $ 40,344     $ 56,748                 BOLT BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands)       Six Months Ended June 30 ,       2026     2025   CASH FLOWS FROM OPERATING ACTIVITIES:             Net loss   $ (14,964 )   $ (19,601 ) Adjustments to reconcile net loss to net cash used in operating activities:             Depreciation and amortization     374       746   Stock-based compensation expense     1,097       1,334   Accretion of discount on marketable securities     (122 )     (379 ) Gain on sale of property and equipment     (404 )     (288 ) Asset impairment     808       —   Non-cash lease expense     1,347       1,239   Changes in operating assets and liabilities:             Prepaid expenses and other assets     (160 )     (236 ) Accounts payable and accrued expenses     (1,203 )     (3,351 ) Operating lease liabilities     (1,334 )     (1,026 ) Deferred revenue     (2 )     (1,533 ) Other long-term liabilities     —       133   Net cash used in operating activities     (14,563 )     (22,962 ) CASH FLOWS FROM INVESTING ACTIVITIES:             Purchases of property and equipment     (13 )     —   Proceeds from sales of property and equipment     717       963   Purchases of marketable securities     (1,230 )     (15,457 ) Maturities of marketable securities     16,221       39,838   Net cash provided by investing activities     15,695       25,344   CASH FLOWS FROM FINANCING ACTIVITIES:             Proceeds from issuance of common stock     25       14   Net cash provided by financing activities     25       14   NET INCREASE (DECREASE) IN CASH     1,157       2,396   Cash, cash equivalents and restricted cash at beginning of year     13,441       8,970   Cash, cash equivalents and restricted cash at end of period   $ 14,598     $ 11,366   Reconciliation of cash, cash equivalents and restricted cash:             Cash and cash equivalents   $ 12,860     $ 9,601   Restricted cash     1,738       1,765   Total cash, cash equivalents and restricted cash   $ 14,598     $ 11,366   Source: Bolt Biotherapeutics, Inc. 2026 GlobeNewswire, Inc., source Press Releases

View stock analysis, news, and events for Bolt Biotherapeutics, Inc.